Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, et al.
…th Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons from the pioneering work done on shorter MDR-TB treatment …
Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, et al.
…n. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017. Methods This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 …
Song L, Zhang Y, Sun F, Lan Y, Tong J, et al.
…atment have led to concerns about hepatotoxicity in shorter regimens. We evaluated hepatotoxicity in two novel regimens against the standard shorter regimen recommended by the World Health Organization (WHO). Methods Participants from the TB-TRUST and TB-TRUST plus trials were as…
Weng T, Sun F, Li Y, Chen J, Chen X, et al.
… to treat, pressing more effective and innovative treatment regimens. New efficient regimens for MDR-TB have obtained high treatment success rates. However, those regimens without drug susceptibility testing (DST) are also likely to contribute to the emergence of resistance. Prec…
Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb trial found that the addition of delamanid to a background regimen hastened culture conversion; …
Tom Decroo, MD
…nt regimen. Therefore the investigators propose to study if regimens strengthened by using high-dose first-line drugs, either a triple dose of isoniazid or a triple dose of rifampicin, are non-inferior to the WHO recommended levofloxacin-strengthened regimen. If one of both high-…
Rahul Verma
…ifficult and challenging treatment. There are two treatment regimens for MDR-TB treatment. Objectives: To compare the predisposing risk factors and treatment outcomes in two different drug regimens for the treatment of MDR-TB. Material and methods: A field based longitudinal stud…
Muhamad Frendy Setyawan, Ni Made Mertaniasih, Soedarsono Soedarsono
BACKGROUND: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in t…
Mireille Avilaw Mpwate, Eddy Mampuya Mbambu, Christian Nzanza Matanda, Gabriel Mabwaka Lema, Michel Kaswa, et al.
…me between the two groups of patients on AG and bedaquiline regimens. The double-difference method was estimated using regression with fixed-effects. A p value Results: The degree of hearing loss was similar between the two groups at the first month [AGs (28 dB) vs BDQ (30 dB); p…
Rathinam Sridhar
…ntroducing short-course 9–12 months all oral Bdq containing regimens with specific inclusion and exclusion criteria.[1] All oral Bdq-based shorter regimens significantly improved sputum culture conversions and treatment success while reducing mortality and treatment failures.[2] …
P Muneera, Grinish Tamakuwala, Jignesh Gengadiya, Parul Vadgama
…inal outcome, and ADRs in RR-TB patients taking shorter MDR regimens. Materials and Methods: Prospective observational longitudinal study which was carried out in the Department of Respiratory Medicine Department, New Civil Hospital, Surat from January 2019 to June 2020. All pati…
Silva DR, Mello FCQ, Migliori GB
…iven the global burden of tuberculosis, shortened treatment regimens with existing or repurposed drugs are needed to contribute to tuberculosis control. The long duration of treatment of drug-susceptible tuberculosis (DS-TB) is associated with nonadherence and loss to follow up, …
Setyawan MF, Mertaniasih NM, Soedarsono S
Background The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in th…
Shaojun Zhang, Yang Yan, Wenwen Sun, Zhong-Shun Zhang, Heping Xiao, et al.
…s and safety of bedaquiline-containing and bedaquiline-free regimens for treatment of patients with refractory rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB). Methods: Patients with refractory RR/MDR-TB receiving bedaquiline-containing regimens (bedaquiline gro…
Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge BB, et al.
…-resistant strains has created a pressing need for new drug regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new regimens has been challenging due to the slow growth of the pathogen Mycobacterium tuberculosis (MTB), coupled with the large…
Martínez-Campreciós J, Aznar ML, Zacarias A, Terán R, Nindia A, et al.
Background Short all-oral regimens for Rifampicin-resistant tuberculosis (ShORRT) have been a turning point in the treatment of drug-resistant tuberculosis. Despite this, access to drugs, stockouts, or adverse effects may limit the use of the recommended regimens. Methods Pragmat…
Lotz JK, Porter J, Conradie H, Boyles T, Gaunt B, et al.
… study describes outcomes in short and long DR-TB treatment regimens, over 5 years, at two rural treatment sites in SA. Characteristics were analysed for outcome correlates using multivariable logistic regression models. Results Of 282 treatment episodes, 62% were successful, wit…
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, et al.
…ects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. Methods T…
James LP, Klaassen F, Sweeney S, Furin J, Franke MF, et al.
…ging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxa…
Wenhong Zhang, PhD
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB . The TB-T…
Rosu L, Madan J, Worrall E, Tomeny E, Squire B
…rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health system. STRE…
Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW
Background Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB) while shortening the treatment duration have reached late-stage clinical trials. Decisions about whether and how to implement such regimens will require an understanding o…
Tsang CA, Shah N, Armstrong LR, Marks SM
Background In 2016, the World Health Organization (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the conventional 18-24 month regimen) for patients without extrapulmonary TB, pregnancy, a previous second-line T…
Du Y, Qiu C, Chen X, Wang J, Jing W, et al.
Background The emergence of multidrug-resistant tuberculosis (MDR-TB) poses a serious obstacle to global TB control programs. Methods We carried out a prospective, randomized, multicenter study in China that was focused on the potential of a shorter regimen containing clofazimine…
Kohler S, Kohler S, Sitali N, Achar J, Paul N
…ntroduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes. Methods We modelled drug purchase and import costs for 20-month, 9-month and 4- to 6-month TB drug regimens based on 2016-2020 treatment numbers from a TB programme in Karakalp…